Radiation Oncologists


Radiotherapy is the use of radiation, such as X-rays, to kill or injure cancer cells. Radiation treatment for pancreatic cancer may be used before or after surgery, or instead of surgery if the cancer is unresectable.  Radiation treatment may also be used to control symptoms due to local or metastatic disease.
The pancreas and liver are technically challenging to treat with radiotherapy because of the organ moving during breathing and their closeness to “radio-sensitive” structures such as the duodenum, small bowel, stomach, kidneys and spinal cord.  Due to the technical difficulty of treating pancreatic tumours with radiation, the experience of the Radiation Oncology department at RNSH is of utmost importance. We are very well placed to treat these areas as we have extensive experience with sophisticated techniques such as intensity modulated radiotherapy (IMRT), volumetric modulated arc therapy (VMAT) and, more recently, stereotactic radiation treatment.  We have a world-class medical physics team who collaborate actively in ongoing projects such as image guidance, respiratory gating and abdominal compression. These techniques are aimed at increasing the safety, reducing variables such as breathing motion and ensuring precise delivery of radiation to maximise dose to tumour and minimize dose to normal tissue.
Our next area of treatment delivery will include the use of fiducial (implanted) markers to allow tracking of the target and its motion in real time, and also to introduce stereotactic treatment into our armamentarium for locally advanced pancreatic cancer. Radiotherapy is very much a team approach between clinicians, medical physics and our large team of dedicated radiotherapists.


SpecialityRadiation Oncologist
DegreesNeed this info
BiographyAssociate Professor Andrew Kneebone is a radiation oncologist with 20 years of experience in the field of radiation oncology & a pre-eminent authority on radiotherapy of the gastrointestinal & genitourinary cancers. A/Prof Kneebone lectures, presents & teaches, as well as providing expert opinion for national guidelines & steering committees. He has been a member of the Australian Gastro-Intestinal Trials Group (AGITG) and radiotherapy executive since 2005. He has also chaired workshops on optimal radiotherapy techniques for pancreatic cancer. He was one of the Chief Investigators for the “LAP 07” trial which was an international phase III trial exploring the role of erlotinib and chemo-irradiation for locally advanced pancreas cancer. He was responsible for the radiation oncology quality assurance audit across the country for this study. He has been an author on more than 90 publications and an investigator involved with more than $6 million in competitive grants. He has recently been commissioned to co-author a review of radiotherapy in pancreatic cancer which will be published in 2016.


SpecialityRadiation Oncologist
BiographyAssociate Professor George Hruby is a Staff Specialist radiation oncologist at Royal North Shore Hospital with more than 15 years of experience in the field and a special interest in gastrointestinal and genitourinary cancers, as well as melanoma. He is heavily involved in research and clinical trials in these areas, with recent publications on new chemo and radiotherapy combinations for the treatment of pancreatic cancer.


SpecialityRadiation Oncologist
BiographyDr Carol Haddad is a radiation oncologist with specific research and clinical interest in stereotactic body radiotherapy (SBRT). She completed a fellowship in this field in Toronto, Canada and continues to pursue the development and optimisation of the technique in Australia. Carol is the lead clinician in the Liver SBRT program at the Northern Sydney Cancer Centre and is developing the technique further through motion minimisation, dose escalation and optimal image guidance.


SpecialityNuclear Physicist
BiographyDale Bailey is Principal Physicist in the Department of Nuclear Medicine, Royal North Shore Hospital, Sydney and Professor of Medical Radiation Sciences at the University of Sydney. He has published over 120 peer-reviewed scientific articles and edited four textbooks. He is the currently project co-leader for the Neuro-Endocrine Tumour programme (“NETwork”) of Sydney Vital – the Northern Translational Cancer Research Centre, Sydney. His main area of interest has been in the development of quantitative techniques using imaging of in vivo radionuclide tracers in both SPECT (single photon emission computed tomography) and PET (positron emission tomography) and, more recently, internal radionuclide dosimetry. Dale is currently a CI for a number of grants including studying the micro-vascular changes in pulmonary arterial hypertension using ventilation & perfusion SPECT and improving imaging and dosimetry techniques in selective internal radionuclide therapy (SIRT) in liver cancer treated with SIR-Spheres using SPECT & PET.


Nuclear Medicine is the use of radioactive molecules (radionuclides) for the diagnosis, staging, therapy and monitoring of the response of a disease process. A nuclear medicine test which may be used in the diagnosis and staging of pancreatic cancer is Positron Emission Tomography (PET). A sugar molecule tagged with a radionuclide is used to build a picture of which organs are using the most sugar. Tumours are one of the most sugar avid tissues and a PET scan can show the extent of the tumour & whether it has spread locally or more distantly.